度普利尤單抗誘導重度哮喘患者血液嗜酸性粒細胞增多研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

李錫容 ^1,2 ,  謝佳星 ^2,3

1. ;
2. ;
3. ;

Corresponding?author：

謝佳星, Email: jiaxingxie@126.com

Keywords：

DOI：

10.7507/1671-6205.202404084

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李錫容, 謝佳星. 度普利尤單抗誘導重度哮喘患者血液嗜酸性粒細胞增多研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(2): 140-146. doi: 10.7507/1671-6205.202404084 Copy

1.	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-73.
2.	Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed April 27, 2023. Available at: www. ginasthma. org.
3.	Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet, 2012, 380(9842): 651-9.
4.	Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol, 2015, 15(1): 57-65.
5.	Kaur R and Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol, 2019, 144(1): 1-12.
6.	Heffler E, Blasi F, Latorre M, et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract, 2019, 7(5): 1462-1468.
7.	Massoth L, Anderson C, and McKinney KA. Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management. Med Sci (Basel), 2019, 7(4): 53.
8.	Benjamin MR, Stevens WW, Li N, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting. J Allergy Clin Immunol Pract, 2019, 7(3): 1010-1016.
9.	Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. J Am Acad Dermatol, 2021, 84(2): 471-478.
10.	Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol, 2021, 127(1): 49-56. e1.
11.	Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med, 2022, 10(1): 11-25.
12.	Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018, 378(26): 2486-2496.
13.	Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol, 2018, 78 (3 Suppl 1): S28-S36.
14.	Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016, 375(24): 2335-2348.
15.	Tha?i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016, 387(10013): 40-52.
16.	Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020, 145(3): 725-739.
17.	Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209): 1638-1650.
18.	Nakajima S, Yonekura S, Nakamizo S, et al. Dupilumab as a novel treatment option for prurigo nodularis. J Allergy Clin Immunol, 2023, 152(4): 870-872.
19.	Yosipovitch G, Mollanazar N, Stander S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med, 2023, 29(5): 1180-1190.
20.	Lee CJ and Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol, 2024, 22(2): 252-258.
21.	Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med, 2022, 387(25): 2317-2330.
22.	Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology, 2020, 158(1): 111-122. e10.
23.	EMA) EMA. Dupixent: EPAR - product information Internet, 2021. Available at: https://www.ema.
24.	Brusselle GG and Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med, 2022, 386(2): 157-171.
25.	Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy, 2020, 50(7): 789-798.
26.	Eger K, Pet L, Weersink EJM, et al. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract, 2021, 9(7): 2913-2915.
27.	Krings JG, McGregor MC, Bacharier LB, et al. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract, 2019, 7(5): 1379-1392.
28.	Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med, 2018, 378(26): 2475-2485.
29.	Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016, 388(10039): 31-44.
30.	Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med, 2021, 385(24): 2230-2240.
31.	Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·μL^-1. Eur Respir J, 2022, 59(6): 2102577.
32.	Wechsler ME, Klion AD, Paggiaro P, et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract, 2022, 10(10): 2695-2709.
33.	Hilderink JM, Klinkenberg LJJ, Aakre KM, et al. Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med, 2017, 55(7): 1013-1024.
34.	Campisi R, Crimi C, Nolasco S, et al. Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. J Asthma Allergy, 2021, 14: 575-583.
35.	Thelen JC, van Zelst CM, van Brummelen SE, et al. Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study. Respir Med, 2023, 206: 107058.
36.	李游, 林慧敏, 張筱嫻, 等. 度普利尤單抗治療重度哮喘初步療效的臨床觀察研究. 中華結核和呼吸雜志, 2023, 46(9): 909-915.
37.	Caminati M, Fassio A, Alberici F, et al. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group. Allergy, 2024, 79(2): 516-519.
38.	Tanaka S, Tsuji T, Shiotsu S, et al. Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis. Cureus, 2022, 14(5): e25218.
39.	Suzaki I, Tanaka A, Yanai R, et al. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report. BMC Pulm Med, 2023, 23(1): 130.
40.	Descamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res, 2021, 79: 100821.
41.	Kimura A, Takeda A, Ikebukuro T, et al. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect, 2021, 11(1): 3.
42.	Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia. Allergy, 2021, 76(9): 2920-2923.
43.	Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy, 2020, 75(5): 1188-1204.
44.	Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy, 2020, 75(7): 1582-1605.
45.	Kong DH, Kim YK, Kim MR, et al. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci, 2018, 19(4): 1057.
46.	Ryser FS, Yalamanoglu A, Valaperti A, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy, 2023, 78(10): 2712-2723.
47.	Kayaba H, Yamada Y, Cui CH, et al. Expression of VLA-4 on eosinophils decreases in patients with eosinophilia. Int Arch Allergy Immunol, 2001, 125 Suppl 1: 33-7.
48.	Hong SG, Sato N, Legrand F, et al. Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration. Blood, 2020, 136(23): 2667-2678.
49.	Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol, 2000, 164(11): 5935-43.
50.	Nagase H, Miyamasu M, Yamaguchi M, et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol, 2000, 106(6): 1132-9.
51.	Harb H and Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy, 2020, 50(1): 5-14.
52.	Nishiyama Y, Koya T, Nagano K, et al. Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology? Allergol Int, 2022, 71(4): 548-551.
53.	Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol, 2020, 182(5): 1120-1135.
54.	Nagase H, Kudo K, Izumi S, et al. Chemokine receptor expression profile of eosinophils at inflamed tissue sites: Decreased CCR3 and increased CXCR4 expression by lung eosinophils. J Allergy Clin Immunol, 2001, 108(4): 563-9.
55.	Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med, 2022, 16(7): 713-721.
56.	De Corso E, Montuori C, Baroni S, et al. Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study. Eur Arch Otorhinolaryngol, 2024, 281(5): 2429-2440.
57.	Rampi A, Tanzini U, Vinciguerra A, et al. Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study. Int Forum Allergy Rhinol, 2023, 13(12): 2244-2247.
58.	Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther, 2018, 35(5): 737-748.
59.	Li Y, Deng Z, Wen J, et al. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China. Ann Med, 2024, 56(1): 2311843.
60.	Lommatzsch M, Brusselle GG, Canonica GW, et al. Disease-modifying anti-asthmatic drugs. Lancet, 2022, 399(10335): 1664-1668.
61.	Lommatzsch M, Suhling H, Korn S, et al. Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations. Allergy, 2022, 77(9): 2839-2843.
62.	Anai M, Yoshida C, Ozono K, et al. Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis. Allergol Int, 2022, 71(2): 259-261.
63.	Matsumoto T, Sakurai Y, Tashima N, et al. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review. Respirol Case Rep, 2023, 12(1): e01266.
64.	Serajeddini H, Venegas Garrido C, Bhalla A, et al. A case series of dual biologics therapy for severe asthma. J Allergy Clin Immunol Pract, 2023, 11(1): 335-340. e2.
65.	Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J, 2020, 55(1): 1900588.
66.	Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int, 2020, 69(4): 519-548.
67.	Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev, 2019, 28(152): 190054.

1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343-73.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed April 27, 2023. Available at: www. ginasthma. org.
3. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet, 2012, 380(9842): 651-9.
4. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol, 2015, 15(1): 57-65.
5. Kaur R and Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol, 2019, 144(1): 1-12.
6. Heffler E, Blasi F, Latorre M, et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract, 2019, 7(5): 1462-1468.
7. Massoth L, Anderson C, and McKinney KA. Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management. Med Sci (Basel), 2019, 7(4): 53.
8. Benjamin MR, Stevens WW, Li N, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting. J Allergy Clin Immunol Pract, 2019, 7(3): 1010-1016.
9. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. J Am Acad Dermatol, 2021, 84(2): 471-478.
10. Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol, 2021, 127(1): 49-56. e1.
11. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med, 2022, 10(1): 11-25.
12. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018, 378(26): 2486-2496.
13. Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol, 2018, 78 (3 Suppl 1): S28-S36.
14. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016, 375(24): 2335-2348.
15. Tha?i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016, 387(10013): 40-52.
16. Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020, 145(3): 725-739.
17. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209): 1638-1650.
18. Nakajima S, Yonekura S, Nakamizo S, et al. Dupilumab as a novel treatment option for prurigo nodularis. J Allergy Clin Immunol, 2023, 152(4): 870-872.
19. Yosipovitch G, Mollanazar N, Stander S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med, 2023, 29(5): 1180-1190.
20. Lee CJ and Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol, 2024, 22(2): 252-258.
21. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med, 2022, 387(25): 2317-2330.
22. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology, 2020, 158(1): 111-122. e10.
23. EMA) EMA. Dupixent: EPAR - product information Internet, 2021. Available at: https://www.ema.
24. Brusselle GG and Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med, 2022, 386(2): 157-171.
25. Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy, 2020, 50(7): 789-798.
26. Eger K, Pet L, Weersink EJM, et al. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract, 2021, 9(7): 2913-2915.
27. Krings JG, McGregor MC, Bacharier LB, et al. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract, 2019, 7(5): 1379-1392.
28. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med, 2018, 378(26): 2475-2485.
29. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016, 388(10039): 31-44.
30. Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med, 2021, 385(24): 2230-2240.
31. Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·μL^-1. Eur Respir J, 2022, 59(6): 2102577.
32. Wechsler ME, Klion AD, Paggiaro P, et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract, 2022, 10(10): 2695-2709.
33. Hilderink JM, Klinkenberg LJJ, Aakre KM, et al. Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med, 2017, 55(7): 1013-1024.
34. Campisi R, Crimi C, Nolasco S, et al. Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. J Asthma Allergy, 2021, 14: 575-583.
35. Thelen JC, van Zelst CM, van Brummelen SE, et al. Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study. Respir Med, 2023, 206: 107058.
36. 李游, 林慧敏, 張筱嫻, 等. 度普利尤單抗治療重度哮喘初步療效的臨床觀察研究. 中華結核和呼吸雜志, 2023, 46(9): 909-915.
37. Caminati M, Fassio A, Alberici F, et al. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group. Allergy, 2024, 79(2): 516-519.
38. Tanaka S, Tsuji T, Shiotsu S, et al. Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis. Cureus, 2022, 14(5): e25218.
39. Suzaki I, Tanaka A, Yanai R, et al. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report. BMC Pulm Med, 2023, 23(1): 130.
40. Descamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res, 2021, 79: 100821.
41. Kimura A, Takeda A, Ikebukuro T, et al. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect, 2021, 11(1): 3.
42. Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia. Allergy, 2021, 76(9): 2920-2923.
43. Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy, 2020, 75(5): 1188-1204.
44. Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy, 2020, 75(7): 1582-1605.
45. Kong DH, Kim YK, Kim MR, et al. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci, 2018, 19(4): 1057.
46. Ryser FS, Yalamanoglu A, Valaperti A, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy, 2023, 78(10): 2712-2723.
47. Kayaba H, Yamada Y, Cui CH, et al. Expression of VLA-4 on eosinophils decreases in patients with eosinophilia. Int Arch Allergy Immunol, 2001, 125 Suppl 1: 33-7.
48. Hong SG, Sato N, Legrand F, et al. Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration. Blood, 2020, 136(23): 2667-2678.
49. Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol, 2000, 164(11): 5935-43.
50. Nagase H, Miyamasu M, Yamaguchi M, et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol, 2000, 106(6): 1132-9.
51. Harb H and Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy, 2020, 50(1): 5-14.
52. Nishiyama Y, Koya T, Nagano K, et al. Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology? Allergol Int, 2022, 71(4): 548-551.
53. Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol, 2020, 182(5): 1120-1135.
54. Nagase H, Kudo K, Izumi S, et al. Chemokine receptor expression profile of eosinophils at inflamed tissue sites: Decreased CCR3 and increased CXCR4 expression by lung eosinophils. J Allergy Clin Immunol, 2001, 108(4): 563-9.
55. Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med, 2022, 16(7): 713-721.
56. De Corso E, Montuori C, Baroni S, et al. Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study. Eur Arch Otorhinolaryngol, 2024, 281(5): 2429-2440.
57. Rampi A, Tanzini U, Vinciguerra A, et al. Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study. Int Forum Allergy Rhinol, 2023, 13(12): 2244-2247.
58. Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther, 2018, 35(5): 737-748.
59. Li Y, Deng Z, Wen J, et al. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China. Ann Med, 2024, 56(1): 2311843.
60. Lommatzsch M, Brusselle GG, Canonica GW, et al. Disease-modifying anti-asthmatic drugs. Lancet, 2022, 399(10335): 1664-1668.
61. Lommatzsch M, Suhling H, Korn S, et al. Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations. Allergy, 2022, 77(9): 2839-2843.
62. Anai M, Yoshida C, Ozono K, et al. Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis. Allergol Int, 2022, 71(2): 259-261.
63. Matsumoto T, Sakurai Y, Tashima N, et al. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review. Respirol Case Rep, 2023, 12(1): e01266.
64. Serajeddini H, Venegas Garrido C, Bhalla A, et al. A case series of dual biologics therapy for severe asthma. J Allergy Clin Immunol Pract, 2023, 11(1): 335-340. e2.
65. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J, 2020, 55(1): 1900588.
66. Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int, 2020, 69(4): 519-548.
67. Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev, 2019, 28(152): 190054.

Previous Article
支氣管循環生理及其在不同肺疾病中的病理變化
Next Article
黑色素瘤缺乏因子2炎癥小體在非感染性肺部疾病中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

度普利尤單抗誘導重度哮喘患者血液嗜酸性粒細胞增多研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content